SOURCE: IMAP, Inc.

IMAP, Inc.

April 01, 2011 13:40 ET

IMAP's Healthcare Industry Global Report Forecasts Move to Emerging Markets

Emerging Markets Will Be a Major Growth Driver for Pharmaceutical and Biotech Companies

SARASOTA, FL--(Marketwire - April 1, 2011) - IMAP, Inc., an exclusive global merger and acquisition (M&A) organization, announced the findings of its Healthcare Industry Global Report 2011 at its International Mergers and Acquisitions Symposium at the Jumeirah Essex House in New York, N.Y. Focused on the pharmaceutical and biotech industries, the report details M&A activity by country and region, insights on industry trends, and growth projections for the remainder of 2011 and beyond.

In 2010, the pharmaceutical industry saw 548 transactions, representing $51.5 billion in total transaction value. In terms of country, the U.S. led with $25.6 billion in transaction value from 114 transactions. Germany came in second with a transaction value of $5.4 billion from 18 total transactions. India had 48 transactions with $4.9 billion in transaction value while China completed 105 transactions with $3.4 billion in transaction value. Brazil rounded out the top five with $1.9 billion in transaction value from 13 deals. 

"Acquisitions and alliances will continue to transform the market," said Michael Innes, managing director of healthcare investment banking at Morgan Joseph TriArtisan (IMAP New York). "A predicted rise in the standard of living in the emerging markets is anticipated to increase consumption of pharmaceuticals, medical devices and healthcare services resulting in worldwide industry expansion. Emphasis on cost effectiveness in mature markets coupled with the need to diversify product offerings for the emerging markets are driving companies to M&A to consolidate core businesses and gain access to new growth areas."

Emerging markets targeted by pharmaceutical and biotech companies include Argentina, Brazil, China, Egypt, India, Indonesia, Mexico, Pakistan, Poland, Romania, Russia, South Africa, Thailand, Turkey, Ukraine, Venezuela and Vietnam. Collectively these markets are expected to grow 15-17 percent in 2011, boosted by greater government spending on healthcare. China in particular, is expected to deliver explosive growth, as it is currently the world's third largest market for pharmaceutical sales. 

The following are some notable, recent M&A transactions completed by IMAP advisers in the healthcare industry:

  • IMAP advised the Spanish pharmaceutical and active pharmaceutical ingredients (API) production company, Grupo Uriach in its acquisition of the Chinese raw materials company and local leading API producer, Jiangsu Sunlight Pharmaceutical.
  • IMAP advised the Croatian generic pharmaceutical producer, Farmal d.d. in its sale of shares to the German group of generic pharmaceutical companies, Dermapharm AG. 
  • IMAP advised the Brazilian medical diagnostics company, MD1 Diagnósticos in its sale of business operations to Brazilian medical diagnostics company, DASA - Diagnósticos de América S.A.
  • IMAP advised the French DUO LP PRO brand over-the-counter (OTC) products development and distribution company, Terra Sante Group in its sale of capital to the Belgium player in the global OTC market, Omega Pharma NV.
  • IMAP advised the Indian generic pharmaceuticals company, Intas Pharmaceuticals Limited in its purchase of certain product rights of the Canadian generic pharmaceuticals company, Orbus Pharma, Inc.

IMAP periodically conducts reports on all major industries, providing a global perspective on M&A activity for a given period. IMAP's reports are a result of internal information gathered for completed M&A projects from IMAP's more than 400 advisers in nearly 30 countries throughout the world, as well as external industry sources. To view IMAP's complete Healthcare Industry Global Report, visit: http://www.imap.com/imap/media/resources/IMAP_PharmaReport_8_272B8752E0FB3.pdf.

About IMAP
IMAP is an exclusive global organization of leading merger and acquisition advisory firms. Formed in 1973, IMAP is composed of more than 50 offices in nearly 30 countries throughout North and South America, Eastern and Western Europe, Australia and Asia. In 2010, IMAP advisers completed 184 transactions, with an aggregate transaction value of more than $11 billion. IMAP advisers provide strategic merger, acquisition, divestiture and related corporate finance services. Sellers of mid-size companies and corporate acquirers alike rely upon IMAP for essential local market knowledge and industry expertise delivered with unparalleled global reach. Every business day, somewhere in the world, an IMAP adviser is completing an M&A transaction. More information is available via the Internet at www.imap.com.

To arrange an interview with representatives from IMAP's Healthcare Group, or if you are interested in expert commentary from a member of IMAP's global network of advisors, please contact the following:

Contact Information